Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Declaration

This activity will be supported simply by an educational grant from Bausch + Lomb.

Activity Description

Inflammation of the uvea—or uveitis—is conducive to about 10% associated with blindness in people in the United States. Approximately 80% of uveitis is noninfectious in etiology, imposing a substantial socioeconomic impact to affected patients and the particular US health care system every year. A prominent complication is usually uveitic macular edema (UME), which affects up to 30% of all individuals regardless of charge and is the leading cause of blindness in patients with uveitis. Establishing the correct diagnosis of UME is critical. Several advanced imaging technologies are available to assist in ruling out other causes of edema plus monitoring the particular progression associated with inflammation and neovascularization.

Historically, management of sufferers with UME has been challenging due to the lack of treatment guidance and no FDA-approved therapies. Corticosteroids are often the first line of therapy for uveitis and UME, while several steroid agents with differing properties plus routes of administration are usually in use. Moreover, the first agent to gain FDA approval for UME is now available.

In this important educational program on UME, expert faculty discuss the multifactorial pathogenesis of this disease, best practices for the use of imaging technologies in resolving the differential diagnosis associated with UME, and the clinical data supporting the make use of conventional and recently available corticosteroid therapies.

Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the particular management of patients along with uveitic macular edema (UME).

Learning Objectives

Upon successful completion of this particular activity, participants should be better able to:

  • Examine the use of multimodal image resolution to identify UME plus track its progression.
  • Assess the latest evidence regarding the efficacy of standard versus novel corticosteroids in the treatment associated with UME.


Lejla Vajzovic, MD, FASRS
Director, Duke Surgical Vitreoretinal Fellowship Program
Director, Duke Center for Artificial and Regenerative Vision
Co-Director, Fight it out Pediatric Retina and Optic Nerve Middle
Movie director, Duke Eye Center Continuing Medical Education
Director, Duke fAVS and AVS Courses
Associate Professor of Ophthalmology
Adult and Pediatric Vitreoretinal Surgery and Diseases
Duke University Vision Center
Durham, NC

Steven Yeh, MD, FASRS
Teacher and Stanley Truhlsen Jr. Chair in Ophthalmology
Truhlsen Attention Institute
University of Nebraska Medical Center
Omaha, NE
Adjunct Professor
Emory University School associated with Medicine
Atlanta, GA


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Ongoing Medical Schooling (ACCME) in order to provide ongoing medical schooling for physicians.

Credit Designation

Vindico Medical Education and learning designates this enduring material for a maximum of 0. 75 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the particular credit commensurate with the extent of their participation within the activity.

Successful conclusion of this particular CME exercise, which includes participation within the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification system. It is the CME activity provider’s responsibility to submit student completion information to ACCME for the purpose of granting credit.

On successful finalization, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Ongoing Certification credits equivalent in order to the amount of CME credits claimed for that action.

This enduring material is definitely approved with regard to 1 year through the date of original release, December 28, 2022, to Dec 27, 2023.

How to Participate inside This Activity and Obtain CME Credit score

To participate in this CME activity, you must read the objectives, answer the polling plus pretest questions, view the particular content, and complete the posttest plus evaluation. Provide only one (1) proper answer regarding each question. A satisfactory score can be defined as answering 2 of the 3 posttest questions correctly. Upon receipt associated with the completed materials, if a satisfactory score on the particular posttest is achieved, Vindico Medical Training will issue an AMA PRA Category 1 Credit(s) ™ certificate.


Vindico Medical Education adheres to the ACCME’s Standards intended for Integrity and Independence in Accredited Continuing Education. Any individuals in the position in order to control the content of a continuing education and learning activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement from the activity.

Activity Chair and Teachers report the following relevant monetary relationship(s)

Lejla Vajzovic, MD, FASRS
Consultant : Alcon, Alimera, Allergan/AbbVie, Bausch + Lomb, Heidelberg Engineering, Janssen, Novartis, Roche/Genentech

Steven Yeh, MD, FASRS
Consultant: Allergan, Bausch + Lomb, Clearside

Reviewer reports the following relevant economic relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA,

No relevant financial relationships in order to disclose.

Vindico Medical Schooling staff report the following relevant monetary relationship(s)

Zero relevant economic relationships to disclose.

Signed disclosures are on file at Vindico Healthcare Education, Office of Medical Affairs plus Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical training activity may contain references to unlabeled uses associated with US Food and  Drug Administration (FDA)–approved products or to products not approved simply by the FDA for use in the particular United Says.   The faculty members have been made aware of their own obligation in order to disclose such usage. All activity individuals will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education and learning, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed within the USA. © 2022 Vindico Healthcare Education. Almost all rights reserved. No part of this particular publication may be reproduced without written permission from the publisher. The particular material presented at or even in any of Vindico Medical Training continuing medical education activities does not really necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Schooling nor the particular faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may talk about the usage of materials and/or items that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected] com

Leave a Reply

Your email address will not be published. Required fields are marked *